Search Results 2921-2930 of 22477 for oral

  1. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

    TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers. TP-0903 has demonstrated ...

  2. A Study to Evaluate Docetaxel With or Without Bintrafusp Alfa to Treat Patients with Advanced Non-small Cell Lung Cancer - Mayo Clinic

    ... oral calcineurin inhibitors; high potency or oral steroids). Known active human immunodeficiency virus (HIV) infection (defined as patients who are not on ...

  3. Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia - Mayo Clinic

    Patients who have known gastrointestinal (GI) disease or GI procedures which could interfere with the oral absorption or tolerance of alisertib are not ...

  5. Sarcoma - Doctors and departments - Mayo Clinic

    ... Oral and throat cancer, Laryngeal cancer, Salivary gland cancer, Oropharyngeal cancer, Radiation injury, Hypopharyngeal cancer. Show more areas of focus for ...

  6. Salmonella infection - Diagnosis & treatment - Mayo Clinic

    For infants and children who have become dehydrated from diarrhea, vomiting or fever, use oral rehydration solutions that you can buy without a prescription.

  7. A Study to Evaluate the Nrf2 Response in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mayo Clinic

    Diabetes mellitus (fasting glucose > 126 mg/dL or treatment with insulin or oral hypoglycemics). Predicted urine protein excretion in urinalysis >1 g/24 ...

  8. A Study of Pembrolizumab Alone or Combined with CC-486 for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer - Mayo Clinic

    The purpose of the study is to determine the best dose of CC-486 (oral azacitidine) combined with pembrolizumab for the treatment of platinum-resistant ...

  9. Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia - Mayo Clinic

    Oral etoposide (up to 200 mg orally per day) may be given as an alternative ... Antileukemic therapy for the treatment of AML (excluding hydroxyurea or oral ...

  10. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

    Current use of oral corticosteroids, with the exception of inhaled or topical steroids. Dexamethasone will be given only in combination with bortezomib on ...